News stories about CELYAD SA/ADR (NASDAQ:CYAD) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CELYAD SA/ADR earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.8420112629877 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

CELYAD SA/ADR traded down $0.44, reaching $30.85, on Wednesday, according to MarketBeat.com. The company’s stock had a trading volume of 11,068 shares, compared to its average volume of 8,305. The stock has a market cap of $306.00 million, a P/E ratio of -8.71 and a beta of 1.54. CELYAD SA/ADR has a 52 week low of $25.55 and a 52 week high of $64.75. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 0.02.

Several research firms have recently issued reports on CYAD. ValuEngine upgraded shares of CELYAD SA/ADR from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. SunTrust Banks began coverage on shares of CELYAD SA/ADR in a report on Thursday, May 31st. They set a “buy” rating and a $49.00 price objective on the stock. HC Wainwright began coverage on shares of CELYAD SA/ADR in a report on Monday, July 2nd. They set a “buy” rating and a $45.00 price objective on the stock. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “sell” rating to a “hold” rating in a report on Wednesday, May 23rd. Finally, Wells Fargo & Co initiated coverage on shares of CELYAD SA/ADR in a report on Friday, May 25th. They set an “outperform” rating and a $44.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. CELYAD SA/ADR presently has a consensus rating of “Buy” and a consensus target price of $53.00.

About CELYAD SA/ADR

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Insider Buying and Selling by Quarter for CELYAD SA/ADR (NASDAQ:CYAD)

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.